Q3 FY26 Quarterly Results Investor Webinar

• Received 5 purchase orders in Q3 FY26, 4 of which were for HiRise™
• Feedback on HiRise™ application in China received, on track for clearance in H2 CY26
• Progressed work with WEGO Orthopaedics to close sales following NMPA clearance

CurveBeam AI Ltd. reported its Q3 FY26 quarterly results, highlighting several key achievements. The company received 5 purchase orders during the quarter, 4 of which were for its HiRise™ device. Feedback on the HiRise™ application for regulatory clearance in China (NMPA) was received, and the company remains on track for clearance in the second half of the calendar year. This milestone will enable HiRise™ sales in China, including a milestone payment and further payments as sales orders follow. The company also continued its work with WEGO Orthopaedics, developing sales prospects to close following the NMPA clearance. Additionally, the company made progress in advancing its total hip arthroplasty (THA) protocol for one of the other four leading robotic surgery systems, representing an important step in broadening partnerships. The company also received feedback on its FDA 510(k) application for the BMD module for multi-detector computed tomography (MDCT) scans and is compiling the requested clinical review and supplemental analysis to support the FDA file, with the targeted clearance now moved to H2 CY26. Finally, the company announced the appointment of Patrick Fisher, a highly experienced global orthopaedic industry executive, as a non-executive director.

The company notes it remains positive with the outlook for Q4 and is prioritizing installations and collection of receipts from customers. The company expects to be able to meet its business objectives based on current cash, ongoing management initiatives, and access to a range of potential funding alternatives.

The company is finalizing the steps towards collecting expanded clinical data for submission to the vendor's R&D and Regulatory teams, whose reviews are anticipated to lead to the validation of HiRise™. The company is also making progress in advancing its total hip arthroplasty (THA) protocol for one of the other four leading robotic surgery systems, with development underway and continued collaboration supporting integration and optimization of the protocol for use with the system.